Genome engineering is a technique in which a Deoxyribonucleic acid (DNA) is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted by the scientist in genome engineering for the development of novel technologies in genome engineering. For instance, in October 2017, Synthego Corporation launched a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Several genome technologies are under trial for treatment of chronic diseases, and are expected to receive approvals over the forecast period.
Global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).
Figure 1. Global Genome Engineering Market Share (%), by Technology, 2022
Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market over the forecast period.
Key players in market are focusing on developing novel technologies and launching new products for genome engineering, in order to increase their market share. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe's first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR. In 2017, Scientists at Salk Institute for Biological Studies, a scientific research institute located in U.S. modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. Development of such novel technologies is expected to be a major driving factor for growth of the global genome engineering market.
|Base Year:||2021||Market Size in 2022:||US$ 5,205.60 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2020 to 2027 CAGR:||14.3%||2030 Value Projection:||US$ 15,195.74 Mn|
Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group
|Restraints & Challenges:||
Figure 2.Global Genome Engineering Market Share (%), by Region, 2022
Increasing funding and investments for research and development of new genetic engineering technologies is expected to drive market growth.
Increasing funding and investments for research and development of new genetic engineering technologies is expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, would award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in genome engineering technology and also aid in growth of market.
Global Genome Engineering Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs and commodities, by creating disruptions in distribution channels. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global genome engineering market, due to genome engineering technique used in manufacturing vaccines for Covid-19. For instance, in June 2020, according to data published by Scientific American, part of Springer Nature, the covid-19 vaccine was manufactured using genome engineering technology. Scientists use information from the genome of the virus to create a blueprint of select antigens. The blueprint is made of (Deoxyribonucleic acid) DNA or ribonucleic acid (RNA)—molecules that hold genetic instructions. The researchers then inject the DNA or RNA into human cells. The cell’s machinery uses the instructions to make virus antigens that the immune system reacts to. Inovio’s DNA plasmid went into small-scale human trials on April 6 2020 only three months after the SARS-CoV-2 genome was published using genome engineering technique.
Global Genome Engineering Market: Key Developments
In May 23 2022, according to data published by PubMed, researchers at John Innes Centre, used gene editing to turn off a specific molecule in the plant's genome which increased provitamin D3 in both the fruit and leaves of tomato plants. It was then converted to vitamin D3 through exposure to Ultraviolet (UVB) light. Tomatoes gene-edited to produce vitamin D, the vitamin which is obtained by the source of sunlight, could be a simple and sustainable innovation to address a global health problem of vitamin D deficiency. Researchers at John Innes Centre used CRISPR-Cas9 gene editing to make revisions to the genetic code of tomato plants so that provitamin D3 accumulates in the tomato fruit.
On May 16 2022, according to a research study published in Science Daily, researchers have developed a CRISPR-Cas9 approach to enable gene editing in cockroaches. The simple and efficient technique, named "direct parental" CRISPR (DIPA-CRISPR), involves the injection of materials into female adults where eggs are developing rather than into the embryos themselves.
Global Genome Engineering Market: Restraint
High cost of genome engineering technologies is expected to be the major factor, restraining growth of the genome engineering market over the forecast period. For instance, according to the fees chart provided by Yale Genome Editing Center, in 2018, it charged between US$ 8,000 and US$ 15,000 for gene editing facilities. High cost associated with genome engineering facilities is expected to hamper market growth, especially in emerging economies such as India, Brazil, and South Africa. Moreover, genome engineering is a very complex technology and needs high skilled researchers, which limits its adoption rate.
Major players operating in the global genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.
Genome engineering is a process of insertion, deletion, modification or replacement of Deoxyribonucleic acid (DNA) bases in an organism. There are two types of gene therapy, Ex-Vivo gene therapy and In-Vivo gene therapy. Ex-vivo gene therapy involves the transfer of genes in cultured cells and then reintroducing in patient, while in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nucleases (TALEN), and Zinc-finger nucleases (ZFNs). These are innovative genome editing tools that enable researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to other methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.
Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period. Key players in market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. would use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide ribonucleic acid (RNA) products for CRISPR genome engineering.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.